The Radboud University Medical Center in the Netherlands, the Instituto de Medicina Molecular Lisboa in Portugal, and PATH are collaborating on a human trial…
Bristol-Myers Squibb's Opdivo is in more vaccine combo studies than its PD-1/PD-L1 rivals, according to a new report.
Bharat Biotech has initiated a phase 1 trial of its Chikungunya vaccine, while Themis started a phase 2 of its own candidate.
Dendreon unveiled new data at ASCO showing Provenge generates a killer T-cell response that correlates with overall survival.
Bexsero has been helping drive revenue growth for GSK, but now, with an EU approval, Pfizer’s Trumenba is set to challenge it in that lucrative market.
Congolese officials have given initial approval to the use of Merck’s as-yet-unlicensed Ebola shot to combat a local outbreak.
A Sanofi executive has explained the rationale behind the company’s Zika vaccine development plan and is issuing a defense against claims his company is out to…
Inovio is getting closer to producing an effective HIV vaccine. Data from an early-stage clinical study showed that its Pennvax-GP could elicit almost 100%…
A shareholder is taking it to the company’s current and former execs for “gross mismanagement” and other allegations.
GSK's Cervarix may have been the first HPV shot approved in mainland China, but Merck's Gardasil now has an opening to gain the lead.